ADPT — Adaptive Biotechnologies Income Statement
0.000.00%
Last trade - 00:00- $1.17bn
- $1.08bn
- $178.96m
- 58
- 12
- 100
- 57
Annual income statement for Adaptive Biotechnologies, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 98.4 | 154 | 185 | 170 | 179 |
| Cost of Revenue | |||||
| Gross Profit | 75.9 | 105 | 127 | 94.7 | 107 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 251 | 363 | 385 | 397 | 342 |
| Operating Profit | -153 | -209 | -200 | -227 | -163 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -146 | -207 | -200 | -225 | -160 |
| Net Income After Taxes | -146 | -207 | -200 | -225 | -160 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -146 | -207 | -200 | -225 | -159 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -146 | -207 | -200 | -225 | -159 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.11 | -1.48 | -1.39 | -1.38 | -1.02 |